The Surfers and guests Manal Abdelmalek, Naim Alkhouri and Akero Therapeutics Chief Development Officer Kitty Yale discuss sections of theFDA Webcast that centered on clinical and surrogate endpoints
The Surfers and guests Manal Abdelmalek, Naim Alkhouri, and Akero Therapeutics Chief Development Officer Kitty Yale share high-level perspectives on the FDA Webcast, both before and after the group’s detailed conversation
Manal Abdelmalek joins the Surfers to discuss key themes they hope to hear at the January 29 FDA Webcast on NASH Drug Development
Manal Abdelmalek joins the Surfers to discuss key themes they hope to hear at the January 29 FDA Webcast on NASH Drug Development
Manal Abdelmalek, Naim Alkhouri and Akero Therapeutics Chief Development Officer Kitty Yale join the Surfers to discuss Friday’s FDA webcast on NASH Drug Development.
Manal Abdelmalek joins the Surfers to share expectations in advance of Friday’s FDA Webcast on NASH Drug Development
The Surfers discuss ways that COVID-19 Vaccine Centers might present an opportunity to educate and screen patients on Liver Health
Donna Cryer and Louise Campbell discuss how governmental action (or inaction) couple with community efforts to shape Liver Health initiatives in the US, UK, and Australia.
Donna Cryer joins the Surfers to explore efforts to support residents in disadvantaged minority communities in the US, UK and Australia in improving their Liver Health and awareness.
The Surfers end this episode by discussing the need for public education to create the awareness necessary for change
Evaluating the economic and patient-motivating value of enhanced telemedicine and mobile non-invasive testing technologies in improving NAFLD diagnosis and lowering rates of non-communicable disease
Innovations in Telemedicine and Mobile Technologies are already changing patient care in ways that will remain and expand in the “New Normal” after the COVID-19 pandemic is less urgent
Manal Abdelmalek joins the Surfers to describe long-term changes in patient management that improved diagnostic and telecommunication technologies can drive in response to new COVID-19 induced challenges
The discussion turns toward a question: if NALFD patients have poorer COVID-19 prognoses, how can we use this fact to drive broader population-based screening?
The COVID-19 conversation continues with the group focusing on challenges in clinical trial execution and how innovative logistics and consistent education can lessen or overcome them
Manal Abdelmalek joins the Surfers to consider the three most important COVID-19 stories today.
Manal Abdelmalek joins the Surfers to discuss how recent COVID-19 news might affect Fatty Liver patients and what the medical profession and BioPharma companies can do to support patients better during this dangerous phase of the pandemic.
